Login to Your Account

Pharma: Other News To Note

Thursday, September 12, 2013
• Merck and Co. Inc., of Whitehouse Station, N.J., licensed its oral small-molecule inhibitor of WEE1 kinase (MK-1775) to Astrazeneca plc, of London.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription